c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia.
Lucas, Claire M
c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia. [electronic resource] - Haematologica May 2015 - e179-82 p. digital
Publication Type: Letter
1592-8721
10.3324/haematol.2014.115691 doi
Autoantigens--metabolism
Cell Line, Tumor
Enzyme Activation--drug effects
Fusion Proteins, bcr-abl--metabolism
Humans
Intracellular Signaling Peptides and Proteins
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--diagnosis
Membrane Proteins--metabolism
Proto-Oncogene Proteins c-myc--antagonists & inhibitors
RNA Interference
RNA, Small Interfering--genetics
Thiazoles--pharmacology
c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia. [electronic resource] - Haematologica May 2015 - e179-82 p. digital
Publication Type: Letter
1592-8721
10.3324/haematol.2014.115691 doi
Autoantigens--metabolism
Cell Line, Tumor
Enzyme Activation--drug effects
Fusion Proteins, bcr-abl--metabolism
Humans
Intracellular Signaling Peptides and Proteins
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--diagnosis
Membrane Proteins--metabolism
Proto-Oncogene Proteins c-myc--antagonists & inhibitors
RNA Interference
RNA, Small Interfering--genetics
Thiazoles--pharmacology